Advertisement

Archives of Gynecology and Obstetrics

, Volume 283, Issue 2, pp 299–304 | Cite as

Oxidant/antioxidant status in premenstrual syndrome

  • Candan Iltemir DuvanEmail author
  • Ahmet Cumaoglu
  • Nilgun Ozturk Turhan
  • Cimen Karasu
  • Hasan Kafali
General Gynecology

Abstract

Purpose

To investigate oxidant/antioxidant status in premenstrual syndrome (PMS).

Methods

Study group (n = 20) consisted of PMS and control group (n = 21) consisted of normal menstruating women. The serum oxidant status was assessed by the lipid hydroperoxide (LHP), malondialdehyde (MDA) and protein carbonyl (PC); the antioxidant status was assessed by the total thiol (T-SH) and total antioxidant capacity (TAC).

Results

The study and control groups revealed no statistical difference, in terms of day 3 LHP, MDA, PC, T-SH and TAC levels. There were no significant differences between groups in terms of day 21 MDA, PC and T-SH levels. However, day 21 LHP levels were increased and TAC levels were decreased in the study group compared with the control group.

Conclusion

Increased oxidative stress and reduced antioxidant capacity may occur in PMS. It can be speculated that the imbalance of oxidant/antioxidant systems may be a cause or the consequence of the various stress symptoms in PMS.

Keywords

Premenstrual syndrome Oxidative stress Antioxidant status 

Notes

Conflict of interest statement

I certify that no actual or potential conflict of interest in relation to this article exists.

References

  1. 1.
    Freeman EW (2003) Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 28:25–37CrossRefPubMedGoogle Scholar
  2. 2.
    Halbreich U (2004) The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder-clinical procedures and research perspectives. Gynecol Endocrinol 19:320–334CrossRefPubMedGoogle Scholar
  3. 3.
    Steiner M, Pearlstein T, Cohen LS, Endicott J, Kornstein SG, Roberts C et al (2006) Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs. J Womens Health 15:57–69CrossRefGoogle Scholar
  4. 4.
    Halbreich U, Borenstein J, Pearlstein T, Kahn LS (2003) The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 28:1–23Google Scholar
  5. 5.
    Alpay FB, Turhan NO (2001) Intermittent versus continuous sertraline therapy in the treatment of premenstrual dysphoric disorders. Int J Fertil Womens Med 46:228–231PubMedGoogle Scholar
  6. 6.
    Halbreich U (2003) The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 28:55–99CrossRefGoogle Scholar
  7. 7.
    Kendler KS, Karkowski LM, Corey LA, Neale MC (1998) Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 155:1234–1240PubMedGoogle Scholar
  8. 8.
    Reame NE, Marshall JC, Kelch RP (1992) Pulsatile LH secretion in women with premenstrual syndrome (PMS): evidence for normal neuroregulation of the menstrual cycle. Psychoneuroendocrinology 17:205–213CrossRefPubMedGoogle Scholar
  9. 9.
    Bäckström T, Andersson A, Andreé L, Birzniece V, Bixo M, Björn I et al (2003) Pathogenesis in menstrual cycle-linked CNS disorders. Ann N Y Acad Sci 1007:42–53CrossRefPubMedGoogle Scholar
  10. 10.
    Evans MD, Dizdaroglu M, Cooke MS (2004) Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 567:1–61CrossRefPubMedGoogle Scholar
  11. 11.
    Madamanchi NR, Vendrov A, Runge MS (2005) Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25:29–38CrossRefPubMedGoogle Scholar
  12. 12.
    Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R (2003) Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8:365–370CrossRefPubMedGoogle Scholar
  13. 13.
    Arranz L, Guayerbas N, De la Fuente M (2007) Impairment of several immune functions in anxious women. J Psychosom Res 62:1–8CrossRefPubMedGoogle Scholar
  14. 14.
    Harma M, Harma M, Erel O (2005) Measurement of the total antioxidant response in preeclampsia with a novel automated method. Eur J Obstet Gynecol Reprod Biol 118:47–51CrossRefPubMedGoogle Scholar
  15. 15.
    Harma M, Harma M, Kocyigit A (2004) Comparison of protein carbonyl and total plasma thiol concentrations in patients with complete hydatidiform mole with those in healthy pregnant women. Acta Obstet Gynecol Scand 83:857–860PubMedGoogle Scholar
  16. 16.
    Lagod L, Paszkowski T, Sikorski R, Rola R (2001) The antioxidant prooxidant balance in pregnancy complicated by spontaneous abortion. Ginekol Pol 72:1073–1078PubMedGoogle Scholar
  17. 17.
    Freemen E, Rickels K, Sondheimer SJ, Polansky M (1990) Ineffectiveness of progesteron suppository treatment for premenstrual syndrome. JAMA 264:349–353CrossRefGoogle Scholar
  18. 18.
    Zadeh-Nourooz J, Tajaddini-Sarmadi J, Wolff S (1994) Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal Biochem 220:403–409CrossRefGoogle Scholar
  19. 19.
    Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358CrossRefPubMedGoogle Scholar
  20. 20.
    Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205CrossRefPubMedGoogle Scholar
  21. 21.
    Benzie IF, Strain JJ (1999) Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Method Enzymol 299:15–27CrossRefGoogle Scholar
  22. 22.
    Korzekwa MI, Steiner M (1997) Premenstrual syndromes. Clin Obstet Gynecol 40:564–576CrossRefPubMedGoogle Scholar
  23. 23.
    Kalia G, Sudheendran S, Rao A (2001) Antioxidant status and lipid peroxidation in premenstrual syndrome: a preliminary study. Clin Chim Acta 309:97–99CrossRefPubMedGoogle Scholar
  24. 24.
    Balat O, Dikensoy E, Ugur MG, Atmaca R, Cekmen M, Yurekli M (2007) Malon dialdehyde, nitrite and adrenomedullin levels in patients with premenstrual syndrome. Arch Gynecol Obstet 275:361–365CrossRefPubMedGoogle Scholar
  25. 25.
    Bäckström T, Sanders D, Leask R, Davidson D, Warner P, Bancroft J (1983) Mood, sexuality, hormones, and the menstrual cycle II: hormone levels and their relationship to the premenstrual syndrome. Psychosom Med 45:503–507PubMedGoogle Scholar
  26. 26.
    Halbreich U, Endicott J, Goldstein S, Nee J (1986) Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 74:576–586CrossRefPubMedGoogle Scholar
  27. 27.
    Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW et al (2000) SPECT [I-123] iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 47:96–106CrossRefPubMedGoogle Scholar
  28. 28.
    Smith MJ, Adams LF, Schmidt PJ, Rubinow DR, Wassermann EM (2003) Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biol Psychiatry 54:757–762CrossRefPubMedGoogle Scholar
  29. 29.
    Rammal H, Bouayed J, Younos C, Soulimani R (2008) Evidence that oxidative stress is linked to anxiety-related behaviour in mice. Brain Behav Immun 22:1156–1159CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Candan Iltemir Duvan
    • 1
    Email author
  • Ahmet Cumaoglu
    • 2
  • Nilgun Ozturk Turhan
    • 1
  • Cimen Karasu
    • 3
  • Hasan Kafali
    • 1
  1. 1.Department of Obstetric and GynecologyUniversity of FatihAnkaraTurkey
  2. 2.Department of BiochemistryUniversity of GaziAnkaraTurkey
  3. 3.Department of PharmacologyUniversity of GaziAnkaraTurkey

Personalised recommendations